Vyne Historical Income Statement
| VYNE Stock | USD 3.18 0.05 1.55% |
Historical analysis of Vyne Therapeutics income statement accounts such as Interest Expense of 13 M, Selling General Administrative of 12.7 M, Other Operating Expenses of 58.3 M or Research Development of 30.9 M can show how well Vyne Therapeutics performed in making a profits. Evaluating Vyne Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vyne Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Vyne Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vyne Therapeutics is a good buy for the upcoming year.
Vyne |
About Vyne Income Statement Analysis
Vyne Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vyne Therapeutics shareholders. The income statement also shows Vyne investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Vyne Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vyne Therapeutics. It is also known as Vyne Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Vyne Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.At present, Vyne Therapeutics' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 30.9 M, whereas Operating Income is forecasted to decline to (30.7 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 11.4M | 477K | 424K | 402.8K | Total Revenue | 14.8M | 477K | 424K | 402.8K |
Vyne Therapeutics income statement Correlations
Click cells to compare fundamentals
Vyne Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vyne Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 2.5M | 4.4M | 5.6M | 10.8M | 12.4M | 13.0M | |
| Selling General Administrative | 22.5M | 89.5M | 54.5M | 16.4M | 13.4M | 12.7M | |
| Other Operating Expenses | 76.2M | 134.5M | 82.8M | 34.8M | 29.7M | 58.3M | |
| Operating Income | (76.2M) | (113.5M) | (68.0M) | (34.3M) | (29.3M) | (30.7M) | |
| Ebit | (76.2M) | (251.4M) | (39.0M) | (34.3M) | (29.0M) | (30.5M) | |
| Research Development | 53.8M | 43.5M | 25.0M | 18.4M | 16.3M | 30.9M | |
| Ebitda | (75.5M) | (251.1M) | (38.9M) | (34.2M) | (29.3M) | (30.7M) | |
| Total Operating Expenses | 76.2M | 133.1M | 79.4M | 34.8M | 29.7M | 57.7M | |
| Income Before Tax | (73.7M) | (255.8M) | (73.8M) | (33.9M) | (27.9M) | (29.3M) | |
| Net Income | (70.5M) | (255.6M) | (73.3M) | (33.9M) | (28.5M) | (29.9M) | |
| Net Interest Income | 517K | 3.1M | 2.5M | (4.4M) | (5.6M) | 0.0 | |
| Depreciation And Amortization | 700K | 341K | 109K | 72K | (255K) | (242.3K) | |
| Total Revenue | 1.8M | 21.0M | 14.8M | 477K | 424K | 402.8K | |
| Gross Profit | 93K | 19.6M | 11.4M | 477K | 424K | 402.8K | |
| Net Income From Continuing Ops | (73.7M) | (255.6M) | (73.3M) | (33.9M) | (29.5M) | (31.0M) | |
| Total Other Income Expense Net | 2.5M | (142.4M) | (5.7M) | 363K | 1.4M | 1.5M | |
| Net Income Applicable To Common Shares | (95.2M) | (255.6M) | (73.3M) | (23.2M) | (20.9M) | (21.9M) | |
| Income Tax Expense | (3.2M) | (258K) | (448K) | 13K | 580K | 609K | |
| Reconciled Depreciation | 700K | 341K | 109K | 72K | (155K) | (147.3K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.